"It's too early to reach firm conclusions about the full extent of the overall survival benefit of adding bevacizumab
At a previous medical meeting, researchers reported that treatment with Avastin and chemotherapy extended the time before tumors progressed compared to chemotherapy alone -- achieving the study's primary endpoint.
Genentech intends to seek approval for Avastin in ovarian cancer later this year, pending discussions with the U.S. Food and Drug Administration over how much survival data will be necessary before the drug can be reviewed and potentially approved, said Genentech spokesperson Krysta Pellegrino.
Several other companies are presenting data on ovarian cancer drugs at this year's ASCO meeting, including Exelixis (EXEL - Get Report), Nektar Therapeutics (NKTR - Get Report) and Endocyte (ECYT - Get Report).--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts